Specifically, the Δexon-2 variant lacks the extracellular epitope of CD19, whereas the Δexon-5,6 variant eliminates the transmembrane domain, both significantly reduce the surface presentation of CD19 on tumor cells, hence rendering CAR-T therapy ineffective [1–3]. Here, CD19 is linked to neoplasm.